Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2018

01-03-2018

MicroRNAs and metastasis: small RNAs play big roles

Authors: Jongchan Kim, Fan Yao, Zhenna Xiao, Yutong Sun, Li Ma

Published in: Cancer and Metastasis Reviews | Issue 1/2018

Login to get access

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs regulating post-transcriptional gene expression. They play important roles in many biological processes under physiological or pathological conditions, including development, metabolism, tumorigenesis, metastasis, and immune response. Over the past 15 years, significant insights have been gained into the roles of miRNAs in cancer. Depending on the cancer type, miRNAs can act as oncogenes, tumor suppressors, or metastasis regulators. In this review, we focus on the role of miRNAs as components of molecular networks regulating metastasis. These miRNAs, termed metastamiRs, promote or inhibit metastasis through various mechanisms, including regulation of migration, invasion, colonization, cancer stem cell properties, epithelial-mesenchymal transition, and microenvironment. Some of these metastamiRs represent attractive therapeutic targets for cancer treatment.
Literature
1.
Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116(2), 281–297.PubMedCrossRef
2.
Winter, J., Jung, S., Keller, S., Gregory, R. I., & Diederichs, S. (2009). Many roads to maturity: microRNA biogenesis pathways and their regulation. Nature Cell Biology, 11(3), 228–234.PubMedCrossRef
3.
Gregory, R. I., Yan, K. P., Amuthan, G., Chendrimada, T., Doratotaj, B., Cooch, N., et al. (2004). The microprocessor complex mediates the genesis of microRNAs. Nature, 432(7014), 235–240.PubMedCrossRef
4.
Han, J., Lee, Y., Yeom, K. H., Kim, Y. K., Jin, H., & Kim, V. N. (2004). The Drosha-DGCR8 complex in primary microRNA processing. Genes & Development, 18(24), 3016–3027.CrossRef
5.
Han, J., Lee, Y., Yeom, K. H., Nam, J. W., Heo, I., Rhee, J. K., et al. (2006). Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell, 125(5), 887–901.PubMedCrossRef
6.
Lund, E., Guttinger, S., Calado, A., Dahlberg, J. E., & Kutay, U. (2004). Nuclear export of microRNA precursors. Science, 303(5654), 95–98.PubMedCrossRef
7.
Yi, R., Qin, Y., Macara, I. G., & Cullen, B. R. (2003). Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes & Development, 17(24), 3011–3016.CrossRef
8.
Bohnsack, M. T., Czaplinski, K., & Gorlich, D. (2004). Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA, 10(2), 185–191.PubMedPubMedCentralCrossRef
9.
Ha, M., & Kim, V. N. (2014). Regulation of microRNA biogenesis. Nature Reviews. Molecular Cell Biology, 15(8), 509–524.PubMedCrossRef
10.
11.
Eichhorn, S. W., Guo, H., McGeary, S. E., Rodriguez-Mias, R. A., Shin, C., Baek, D., et al. (2014). mRNA destabilization is the dominant effect of mammalian microRNAs by the time substantial repression ensues. Molecular Cell, 56(1), 104–115.PubMedPubMedCentralCrossRef
12.
Guo, H., Ingolia, N. T., Weissman, J. S., & Bartel, D. P. (2010). Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature, 466(7308), 835–840.PubMedPubMedCentralCrossRef
13.
14.
Massart, J., Katayama, M., & Krook, A. (2016). Micromanaging glucose and lipid metabolism in skeletal muscle: role of microRNAs. Biochimica et Biophysica Acta, 1861(12 Pt B), 2130–2138.PubMedCrossRef
15.
Rupaimoole, R., & Slack, F. J. (2017). MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nature Reviews. Drug Discovery, 16(3), 203–222.PubMedCrossRef
16.
17.
18.
Trobaugh, D. W., & Klimstra, W. B. (2017). MicroRNA regulation of RNA virus replication and pathogenesis. Trends in Molecular Medicine, 23(1), 80–93.PubMedCrossRef
19.
Xiao, C., & Rajewsky, K. (2009). MicroRNA control in the immune system: basic principles. Cell, 136(1), 26–36.PubMedCrossRef
20.
Ling, H., Fabbri, M., & Calin, G. A. (2013). MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nature Reviews. Drug Discovery, 12(11), 847–865.PubMedPubMedCentralCrossRef
21.
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., et al. (2002). Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 99(24), 15524–15529.PubMedPubMedCentralCrossRef
22.
Klein, U., Lia, M., Crespo, M., Siegel, R., Shen, Q., Mo, T., et al. (2010). The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell, 17(1), 28–40.PubMedCrossRef
23.
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., et al. (2005). MicroRNA expression profiles classify human cancers. Nature, 435(7043), 834–838.PubMedCrossRef
24.
He, L., Thomson, J. M., Hemann, M. T., Hernando-Monge, E., Mu, D., Goodson, S., et al. (2005). A microRNA polycistron as a potential human oncogene. Nature, 435(7043), 828–833.PubMedPubMedCentralCrossRef
25.
Xiao, C., Srinivasan, L., Calado, D. P., Patterson, H. C., Zhang, B., Wang, J., et al. (2008). Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nature Immunology, 9(4), 405–414.PubMedPubMedCentralCrossRef
26.
Krichevsky, A. M., & Gabriely, G. (2009). MiR-21: a small multi-faceted RNA. Journal of Cellular and Molecular Medicine, 13(1), 39–53.PubMedCrossRef
27.
Hatley, M. E., Patrick, D. M., Garcia, M. R., Richardson, J. A., Bassel-Duby, R., van Rooij, E., et al. (2010). Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell, 18(3), 282–293.PubMedPubMedCentralCrossRef
28.
Medina, P. P., Nolde, M., & Slack, F. J. (2010). OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature, 467(7311), 86–90.PubMedCrossRef
29.
Pasquinelli, A. E., Reinhart, B. J., Slack, F., Martindale, M. Q., Kuroda, M. I., Maller, B., et al. (2000). Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature, 408(6808), 86–89.PubMedCrossRef
30.
31.
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., et al. (2005). RAS is regulated by the let-7 microRNA family. Cell, 120(5), 635–647.PubMedCrossRef
32.
Esquela-Kerscher, A., Trang, P., Wiggins, J. F., Patrawala, L., Cheng, A., Ford, L., et al. (2008). The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle, 7(6), 759–764.PubMedCrossRef
33.
He, X., He, L., & Hannon, G. J. (2007). The guardian’s little helper: microRNAs in the p53 tumor suppressor network. Cancer Research, 67(23), 11099–11101.PubMedCrossRef
34.
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., et al. (2007). A microRNA component of the p53 tumour suppressor network. Nature, 447(7148), 1130–1134.PubMedPubMedCentralCrossRef
35.
Concepcion, C. P., Han, Y. C., Mu, P., Bonetti, C., Yao, E., D'Andrea, A., et al. (2012). Intact p53-dependent responses in miR-34-deficient mice. PLoS Genetics, 8(7), e1002797.PubMedPubMedCentralCrossRef
36.
Cheng, C. Y., Hwang, C. I., Corney, D. C., Flesken-Nikitin, A., Jiang, L., Oner, G. M., et al. (2014). MiR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment. Cell Reports, 6(6), 1000–1007.PubMedPubMedCentralCrossRef
37.
Brabletz, T., Lyden, D., Steeg, P. S., & Werb, Z. (2013). Roadblocks to translational advances on metastasis research. Nature Medicine, 19(9), 1104–1109.PubMedPubMedCentralCrossRef
38.
Wan, L., Pantel, K., & Kang, Y. (2013). Tumor metastasis: moving new biological insights into the clinic. Nature Medicine, 19(11), 1450–1464.PubMedCrossRef
39.
40.
Talmadge, J. E., & Fidler, I. J. (2010). AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Research, 70(14), 5649–5669.PubMedPubMedCentralCrossRef
41.
42.
Sun, Y., & Ma, L. (2015). The emerging molecular machinery and therapeutic targets of metastasis. Trends in Pharmacological Sciences, 36(6), 349–359.PubMedPubMedCentralCrossRef
43.
Ma, L., Teruya-Feldstein, J., & Weinberg, R. A. (2007). Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 449(7163), 682–688.PubMedCrossRef
44.
Ma, L., Reinhardt, F., Pan, E., Soutschek, J., Bhat, B., Marcusson, E. G., et al. (2010). Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nature Biotechnology, 28(4), 341–347.PubMedPubMedCentralCrossRef
45.
46.
Yoo, B., Kavishwar, A., Ross, A., Wang, P., Tabassum, D. P., Polyak, K., et al. (2015). Combining miR-10b-targeted nanotherapy with low-dose doxorubicin elicits durable regressions of metastatic breast cancer. Cancer Research, 75(20), 4407–4415.PubMedPubMedCentralCrossRef
47.
Yoo, B., Kavishwar, A., Wang, P., Ross, A., Pantazopoulos, P., Dudley, M., et al. (2017). Therapy targeted to the metastatic niche is effective in a model of stage IV breast cancer. Scientific Reports, 7, 45060.PubMedPubMedCentralCrossRef
48.
Kim, J., Siverly, A. N., Chen, D., Wang, M., Yuan, Y., Wang, Y., et al. (2016). Ablation of miR-10b suppresses oncogene-induced mammary tumorigenesis and metastasis and reactivates tumor-suppressive pathways. Cancer Research, 76(21), 6424–6435.PubMedPubMedCentralCrossRef
49.
Myers, C., Charboneau, A., Cheung, I., Hanks, D., & Boudreau, N. (2002). Sustained expression of homeobox D10 inhibits angiogenesis. The American Journal of Pathology, 161(6), 2099–2109.PubMedPubMedCentralCrossRef
50.
Chai, G., Liu, N., Ma, J., Li, H., Oblinger, J. L., Prahalad, A. K., et al. (2010). MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1. Cancer Science, 101(9), 1997–2004.PubMedCrossRef
51.
Tian, Y., Luo, A., Cai, Y., Su, Q., Ding, F., Chen, H., et al. (2010). MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal cancer cell lines. The Journal of Biological Chemistry, 285(11), 7986–7994.PubMedPubMedCentralCrossRef
52.
Ma, L., Young, J., Prabhala, H., Pan, E., Mestdagh, P., Muth, D., et al. (2010). MiR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nature Cell Biology, 12(3), 247–256.PubMedPubMedCentral
53.
Chen, D., Sun, Y., Wei, Y., Zhang, P., Rezaeian, A. H., Teruya-Feldstein, J., et al. (2012). LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nature Medicine, 18(10), 1511–1517.PubMedPubMedCentralCrossRef
54.
Johnson, R. W., Finger, E. C., Olcina, M. M., Vilalta, M., Aguilera, T., Miao, Y., et al. (2016). Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Nature Cell Biology, 18(10), 1078–1089.PubMedPubMedCentralCrossRef
55.
Luo, Q., Wang, C., Jin, G., Gu, D., Wang, N., Song, J., et al. (2015). LIFR functions as a metastasis suppressor in hepatocellular carcinoma by negatively regulating phosphoinositide 3-kinase/AKT pathway. Carcinogenesis, 36(10), 1201–1212.PubMedCrossRef
56.
Sachdeva, M., Mito, J. K., Lee, C. L., Zhang, M., Li, Z., Dodd, R. D., et al. (2014). MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes. The Journal of Clinical Investigation, 124(10), 4305–4319.PubMedPubMedCentralCrossRef
57.
Segura, M. F., Hanniford, D., Menendez, S., Reavie, L., Zou, X., Alvarez-Diaz, S., et al. (2009). Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proceedings of the National Academy of Sciences of the United States of America, 106(6), 1814–1819.PubMedPubMedCentralCrossRef
58.
Tavazoie, S. F., Alarcon, C., Oskarsson, T., Padua, D., Wang, Q., Bos, P. D., et al. (2008). Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 451(7175), 147–152.PubMedPubMedCentralCrossRef
59.
Song, G., Zhang, Y., & Wang, L. (2009). MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. The Journal of Biological Chemistry, 284(46), 31921–31927.PubMedPubMedCentralCrossRef
60.
Png, K. J., Halberg, N., Yoshida, M., & Tavazoie, S. F. (2011). A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature, 481(7380), 190–194.PubMedCrossRef
61.
Zhang, Y., Yang, P., Sun, T., Li, D., Xu, X., Rui, Y., et al. (2013). MiR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nature Cell Biology, 15(3), 284–294.PubMedPubMedCentralCrossRef
62.
Liu, H., Patel, M. R., Prescher, J. A., Patsialou, A., Qian, D., Lin, J., et al. (2010). Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proceedings of the National Academy of Sciences of the United States of America, 107(42), 18115–18120.PubMedPubMedCentralCrossRef
63.
Malanchi, I., Santamaria-Martinez, A., Susanto, E., Peng, H., Lehr, H. A., Delaloye, J. F., et al. (2011). Interactions between cancer stem cells and their niche govern metastatic colonization. Nature, 481(7379), 85–89.PubMedCrossRef
64.
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100(7), 3983–3988.PubMedPubMedCentralCrossRef
65.
Yu, F., Yao, H., Zhu, P., Zhang, X., Pan, Q., Gong, C., et al. (2007). Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell, 131(6), 1109–1123.PubMedCrossRef
66.
Dangi-Garimella, S., Yun, J., Eves, E. M., Newman, M., Erkeland, S. J., Hammond, S. M., et al. (2009). Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. The EMBO Journal, 28(4), 347–358.PubMedPubMedCentralCrossRef
67.
Yun, J., Frankenberger, C. A., Kuo, W. L., Boelens, M. C., Eves, E. M., Cheng, N., et al. (2011). Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer. The EMBO Journal, 30(21), 4500–4514.PubMedPubMedCentralCrossRef
68.
Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun-Davis, T., Li, H., et al. (2011). The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nature Medicine, 17(2), 211–215.PubMedPubMedCentralCrossRef
69.
Liu, C., Liu, R., Zhang, D., Deng, Q., Liu, B., Chao, H. P., et al. (2017). MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nature Communications, 8, 14270.PubMedPubMedCentralCrossRef
70.
Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S., & Yang, J. (2012). Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell, 22(6), 725–736.PubMedPubMedCentralCrossRef
71.
Tsai, J. H., & Yang, J. (2013). Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes & Development, 27(20), 2192–2206.CrossRef
72.
Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., et al. (2008). The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature Cell Biology, 10(5), 593–601.PubMedCrossRef
73.
Park, S. M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008). The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes & Development, 22(7), 894–907.CrossRef
74.
Burk, U., Schubert, J., Wellner, U., Schmalhofer, O., Vincan, E., Spaderna, S., et al. (2008). A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Reports, 9(6), 582–589.PubMedPubMedCentralCrossRef
75.
Gregory, P. A., Bracken, C. P., Smith, E., Bert, A. G., Wright, J. A., Roslan, S., et al. (2011). An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Molecular Biology of the Cell, 22(10), 1686–1698.PubMedPubMedCentralCrossRef
76.
Zhang, P., Wang, L., Rodriguez-Aguayo, C., Yuan, Y., Debeb, B. G., Chen, D., et al. (2014). MiR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nature Communications, 5, 5671.PubMedPubMedCentralCrossRef
77.
Gibbons, D. L., Lin, W., Creighton, C. J., Rizvi, Z. H., Gregory, P. A., Goodall, G. J., et al. (2009). Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes & Development, 23(18), 2140–2151.CrossRef
78.
Dykxhoorn, D. M., Wu, Y., Xie, H., Yu, F., Lal, A., Petrocca, F., et al. (2009). MiR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One, 4(9), e7181.PubMedPubMedCentralCrossRef
79.
Korpal, M., Ell, B. J., Buffa, F. M., Ibrahim, T., Blanco, M. A., Celia-Terrassa, T., et al. (2011). Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nature Medicine, 17(9), 1101–1108.PubMedPubMedCentralCrossRef
80.
Chou, J., Lin, J. H., Brenot, A., Kim, J. W., Provot, S., & Werb, Z. (2013). GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nature Cell Biology, 15(2), 201–213.PubMedPubMedCentralCrossRef
81.
Martello, G., Rosato, A., Ferrari, F., Manfrin, A., Cordenonsi, M., Dupont, S., et al. (2010). A microRNA targeting dicer for metastasis control. Cell, 141(7), 1195–1207.PubMedCrossRef
82.
Chen, D., Sun, Y., Yuan, Y., Han, Z., Zhang, P., Zhang, J., et al. (2014). MiR-100 induces epithelial-mesenchymal transition but suppresses tumorigenesis, migration and invasion. PLoS Genetics, 10(2), e1004177.PubMedPubMedCentralCrossRef
83.
Song, S. J., Poliseno, L., Song, M. S., Ala, U., Webster, K., Ng, C., et al. (2013). MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell, 154(2), 311–324.PubMedPubMedCentralCrossRef
84.
Krzeszinski, J. Y., Wei, W., Huynh, H., Jin, Z., Wang, X., Chang, T. C., et al. (2014). MiR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature, 512(7515), 431–435.PubMedCrossRef
85.
Ell, B., Mercatali, L., Ibrahim, T., Campbell, N., Schwarzenbach, H., Pantel, K., et al. (2013). Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell, 24(4), 542–556.PubMedCrossRef
86.
Singh, R., Pochampally, R., Watabe, K., Lu, Z., & Mo, Y. Y. (2014). Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer. Molecular Cancer, 13, 256.PubMedPubMedCentralCrossRef
87.
Zhuang, G., Wu, X., Jiang, Z., Kasman, I., Yao, J., Guan, Y., et al. (2012). Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. The EMBO Journal, 31(17), 3513–3523.PubMedPubMedCentralCrossRef
88.
Zhou, W., Fong, M. Y., Min, Y., Somlo, G., Liu, L., Palomares, M. R., et al. (2014). Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell, 25(4), 501–515.PubMedPubMedCentralCrossRef
89.
Fong, M. Y., Zhou, W., Liu, L., Alontaga, A. Y., Chandra, M., Ashby, J., et al. (2015). Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nature Cell Biology, 17(2), 183–194.PubMedPubMedCentralCrossRef
90.
Zhang, L., Zhang, S., Yao, J., Lowery, F. J., Zhang, Q., Huang, W. C., et al. (2015). Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature, 527(7576), 100–104.PubMedPubMedCentralCrossRef
91.
Merritt, W. M., Lin, Y. G., Han, L. Y., Kamat, A. A., Spannuth, W. A., Schmandt, R., et al. (2008). Dicer, Drosha, and outcomes in patients with ovarian cancer. The New England Journal of Medicine, 359(25), 2641–2650.PubMedPubMedCentralCrossRef
92.
Torres, A., Torres, K., Paszkowski, T., Jodlowska-Jedrych, B., Radomanski, T., Ksiazek, A., et al. (2011). Major regulators of microRNAs biogenesis Dicer and Drosha are down-regulated in endometrial cancer. Tumour Biology, 32(4), 769–776.PubMedPubMedCentralCrossRef
93.
Rupaimoole, R., Ivan, C., Yang, D., Gharpure, K. M., Wu, S. Y., Pecot, C. V., et al. (2016). Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene, 35(33), 4312–4320.PubMedPubMedCentralCrossRef
94.
Su, X., Chakravarti, D., Cho, M. S., Liu, L., Gi, Y. J., Lin, Y. L., et al. (2010). TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature, 467(7318), 986–990.PubMedPubMedCentralCrossRef
95.
van den Beucken, T., Koch, E., Chu, K., Rupaimoole, R., Prickaerts, P., Adriaens, M., et al. (2014). Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nature Communications, 5, 5203.PubMedPubMedCentralCrossRef
96.
Shen, J., Xia, W., Khotskaya, Y. B., Huo, L., Nakanishi, K., Lim, S. O., et al. (2013). EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature, 497(7449), 383–387.PubMedPubMedCentralCrossRef
97.
Salmena, L., Poliseno, L., Tay, Y., Kats, L., & Pandolfi, P. P. (2011). A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell, 146(3), 353–358.PubMedPubMedCentralCrossRef
98.
Bosson, A. D., Zamudio, J. R., & Sharp, P. A. (2014). Endogenous miRNA and target concentrations determine susceptibility to potential ceRNA competition. Molecular Cell, 56(3), 347–359.PubMedPubMedCentralCrossRef
99.
Denzler, R., Agarwal, V., Stefano, J., Bartel, D. P., & Stoffel, M. (2014). Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance. Molecular Cell, 54(5), 766–776.PubMedPubMedCentralCrossRef
100.
Poliseno, L., Salmena, L., Zhang, J., Carver, B., Haveman, W. J., & Pandolfi, P. P. (2010). A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature, 465(7301), 1033–1038.PubMedPubMedCentralCrossRef
101.
Karreth, F. A., Tay, Y., Perna, D., Ala, U., Tan, S. M., Rust, A. G., et al. (2011). In vivo identification of tumor-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell, 147(2), 382–395.PubMedPubMedCentralCrossRef
102.
Tay, Y., Kats, L., Salmena, L., Weiss, D., Tan, S. M., Ala, U., et al. (2011). Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell, 147(2), 344–357.PubMedPubMedCentralCrossRef
Metadata
Title
MicroRNAs and metastasis: small RNAs play big roles
Authors
Jongchan Kim
Fan Yao
Zhenna Xiao
Yutong Sun
Li Ma
Publication date
01-03-2018
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2018
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-017-9712-y

Other articles of this Issue 1/2018

Cancer and Metastasis Reviews 1/2018 Go to the issue

CLINICAL

Current perspectives on bone metastases in castrate-resistant prostate cancer

OriginalPaper

Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy

Announcement

Biographies

OriginalPaper

RNA interference-based therapy and its delivery systems

OriginalPaper

Non-coding RNAs, epigenetics, and cancer: tying it all together

ReviewPaper

miR-155 in cancer drug resistance and as target for miRNA-based therapeutics
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits